{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:51:20Z","timestamp":1787496680815,"version":"build-2736575974"},"reference-count":13,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Oxaliplatin is a third generation anti-neoplastic platinum compound (organo-platinum complex) used in the treatment of several solid tumours either as a single agent or in combination with other chemotherapy drugs. Hypersensitivity reactions to oxaliplatin are uncommon, with most reports indicating an incidence of 1\u20135%. The severity of reactions may vary from grade 1 side effect in line of skin flushing and\/or rashes to very severe, life-threatening systemic anaphylaxis (grade 3\/4). Following mild to moderate hypersensitivity reactions, steroids and\/or antihistamines could be administered, after which the patient can be re-exposed to the drug. In severe hypersensitivity reactions however, oxaliplatin must be discontinued while alternative chemotherapeutic regimen or even other forms of therapy should be considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>A 56\u2009year old woman with colorectal cancer who was commenced on adjuvant oxaliplatin therapy developed Hypersensitivity reaction about 2\u2009hours of the first oxaliplatin administration, for which the drug was discontinued and the symptoms improved. She had similar reactions in 2 subsequent attempts at administering same drug, after which the drug was changed. A placebo infusion was administered twice with no untoward reactions. Management and outcome: With each reaction, the drug was immediately discontinued and she was promptly given intranasal oxygen and corticosteroids. She was premedicated with anti-histamines and corticosteroids prior to subsequent cycles. Oxaliplatin was consequently discontinued and she experienced no further hypersensitivity reaction to the subsequent drug regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Hypersensitivity reactions to oxaliplatin, though a rare occurrence, are more likely idiosyncratic; with more cases being reported in recent times.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220970631","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T03:59:23Z","timestamp":1604289563000},"page":"1258-1260","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Delayed hypersensitivity to oxaliplatin in a nigerian patient with colorectal cancer\u2014A case report"],"prefix":"10.1177","volume":"27","author":[{"given":"Usman M","family":"Aliyu","sequence":"first","affiliation":[{"name":"Department of Clinical and Radiation Oncology, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5067-0211","authenticated-orcid":false,"given":"Charles O","family":"Okwonna","sequence":"additional","affiliation":[{"name":"Department of Clinical and Radiation Oncology, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"bibr1-1078155220970631","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.5b00597"},{"key":"bibr2-1078155220970631","doi-asserted-by":"publisher","DOI":"10.1016\/j.poly.2013.10.003"},{"key":"bibr3-1078155220970631","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2006.n.027"},{"key":"bibr4-1078155220970631","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000132235.38297.7c"},{"key":"bibr5-1078155220970631","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2006.38.4.240"},{"key":"bibr6-1078155220970631","doi-asserted-by":"publisher","DOI":"10.1097\/01.pap.0000249924.90645.5b"},{"key":"bibr7-1078155220970631","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.06.007"},{"key":"bibr8-1078155220970631","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11379"},{"key":"bibr9-1078155220970631","doi-asserted-by":"publisher","DOI":"10.1159\/000178163"},{"key":"bibr10-1078155220970631","first-page":"373","volume":"6","author":"Suenaga M","year":"2008","journal-title":"J Support Oncol"},{"key":"bibr11-1078155220970631","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.06.021"},{"key":"bibr12-1078155220970631","first-page":"105","volume":"16","author":"Tonini G","year":"2002","journal-title":"J Biol Regul Homeost Agents"},{"key":"bibr13-1078155220970631","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E631"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220970631","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220970631","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220970631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:24:08Z","timestamp":1777688648000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220970631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1177\/1078155220970631"],"URL":"https:\/\/doi.org\/10.1177\/1078155220970631","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]}}}